We are in the forefront of following the new Clinical Research Guidelines and trends from the FDA. Whether its structuring the clinical program to enable a risk-based approach to monitoring or designing the program to assess product efficacy (and safety) at prospective time points thereby adapting the study data collection plan to maximize the ‘interim’